Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 281

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 281
---
ett syndrome, cancer, and potentially other diseases.

DiamiR’s Structure

DiamiR was incorporated in
Delaware on June 16, 2014 and is headquartered in Princeton, New Jersey. DiamiR operates through its wholly-owned operating subsidiary,
DiamiR, LLC (the “Subsidiary”) that was incorporated as a limited liability company in Delaware on September 17, 2009.

On October 1, 2014, DiamiR
entered into a Share Exchange Agreement with DiamiR, LLC, pursuant to which DiamiR acquired 100% of the issued and outstanding units of
DiamiR, LLC in exchange for 4,282,000 shares (100%) of DiamiR’s common stock (the “Share Exchange”), and DiamiR, LLC
became a wholly-owned subsidiary of DiamiR. The Share Exchange is recognized as a combination of entities under common control as
both DiamiR, LLC and DiamiR has been controlled before and after the transaction by the same shareholders. As such, the financial statements
and financial information contained in this filing for prior years has been retrospectively adjusted as if the Share Exchange had
occurred at the beginning of the earliest period presented.

Below is the chart showing
DiamiR’s corporate structure:

<div align='center'>157</div>

DiamiR’s Strategy

DiamiR’s objective is
to improve care for patients with NDs and other diseases by developing and commercializing innovative cost-effective blood-based tests
for early detection and monitoring of pathology. To achieve this objective, DiamiR’s strategy is to:

Identify and validate blood-based miRNA biomarker signatures of different pathologies.DiamiR selects candidate biomarkers among organ-enriched
miRNAs detectable in blood. DiamiR has assembled a proprietary database that incorporates publicly available and proprietary data on a
large number of miRNAs; DiamiR keeps this database up-to-date as new information becomes available.

| ● | DiamiR uses a highly sensitive method for miRNA qualification,                                                                               
 quantitative real-time polymerase chain reaction (“RT-qPCR”), to measure plasma levels of candidate miRNA biomarkers. Quantitative           
 reverse transcription polymerase chain reaction, also called RT-qPCR, is used to detect and quantify levels of miRNA. Extracted              
 miRNA is first transcribed into complementary DNA (cDNA). The cDNA is then used as the template for the quantitative PCR or real-time